Regorafenib for Gastrointestinal Malignancies
- 469 Downloads
Intracellular signals for cancer cell growth, proliferation, migration, and survival are frequently triggered by protein tyrosine kinases (TKs). The possibility of disrupting core disease pathways has led to development and widespread clinical use of specific TK inhibitors that in the past decade have markedly changed treatment strategies and impacted on overall outcomes. However, intrinsic resistance may limit the benefit of these drugs, and multiple escape routes compensate for the inhibited signaling. The disruption of several points of the same pathway and the simultaneous interference with different intracellular oncogenic processes have both been recognized as valuable strategies to maximize the therapeutic potential of this class of agents. In this scenario, regorafenib has emerged as a novel, orally active, multitarget compound with potent activity against a number of angiogenic and stromal TKs, including vascular endothelial growth factor receptor 2 (VEGFR-2), tyrosine kinase with immunoglobulin-like and EGF-like domains 2 (TIE-2), fibroblast growth factor receptor 1 (FGFR-1), and platelet-derived growth factor receptor (PDGFR). Moreover, the drug has the capability of blocking KIT, RET and V600 mutant BRAF. Starting from interesting preclinical results, this review describes the clinical development of regorafenib in gastrointestinal malignancies, focusing on data derived from cutting edge clinical trials that have provided evidence of efficacy in pretreated patients with advanced colorectal cancer or gastrointestinal stromal tumors.
The authors want to thank Dr Jessica Menis, Clinical Fellow, EORTC, Brussels, Belgium and Dr Masoud Saman, Department of Otolaryngology – Head and Neck Surgery, New York Eye and Ear Infirmary, NY, USA for their valuable comments and friendly contribution in reviewing the manuscript.
Competing interest statement
The authors declare they have no competing financial interests.
No sponsors were involved in the writing of the manuscript or in the decision to submit the manuscript for publication.
- 19.E7050 in combination with sorafenib versus sorafenib alone as first line therapy in patients with hepatocellular carcinoma. ClinicalTrials.gov Identifier: NCT01271504. National Institutes of Health. http://www.clinicaltrials.gov.
- 21.Bayer and Onyx settle over regorafenib [editorial]. Nat Rev Drug Discov 2011;10:804–5.Google Scholar
- 29.Park SH, Ryu MH, Ryoo BY, et al. Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean Gastrointestinal Stromal Tumors Study Group. Invest New Drugs. 2012;30:2377–83.Google Scholar
- 30.Ryu M, Park SH, Ryoo B, et al. A phase II study of sorafenib in patients with metastatic or unresectable gastrointestinal stromal tumors with failure of both imatinib and sunitinib: A KGSG study [abstract 10010]. 2011 ASCO Annual Meeting. J Clin Oncol. 2011;29(Suppl).Google Scholar
- 44.Schmieder R, Ellinghaus P, Scholze A., et al. Regorafenib (BAY 73-4506): anti-metastatic activity in a mouse model of colorectal cancer [abstract no. 2337]. 2012 AACR Annual Meeting, 2012 March 31–April 4, Chicago (IL).Google Scholar
- 47.Shimizu T, Tolcher AW, Patnaik A, et al. Phase I dose-escalation study of continuously administered regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors [abstract no. 3035]. 2010 ASCO Annual Meeting, 2010 June 4–8, Chicago (IL).Google Scholar
- 48.Kies MS, Blumenschein GR Jr, Christensen O, et al. Phase I study of regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, administered continuously in patients (pts) with advanced refractory non-small cell lung cancer (NSCLC) [abstract no. 7585]. 2010 ASCO Annual Meeting. J Clin Oncol. 2010;28:(Suppl. 15s).Google Scholar
- 49.Eisen T, Joensuu H, Nathan P, et al. Phase II study of BAY 73-4506, a multikinase inhibitor, in previously untreated patients with metastatic or unresectable renal cell cancer [abstract no. 5033]. 2009 ASCO Annual Meeting. J Clin Oncol. 2009;27:(Suppl. 15s).Google Scholar
- 50.Bolondi L, Tak WY, Gasbarrini A, et al. Phase II safety study of the oral multikinase inhibitor regorafenib (BAY 73-4506) as second-line therapy in patients with hepatocellular carcinoma (HCC) [abstract]. Eur J Cancer. 2011;7:6576.Google Scholar
- 52.Van Den Abbeele AD, Tanaka Y, Locascio T, et al. Assessment of regorafenib activity with FDG-PET/CT in a multicenter phase II study in patients (pts) with advanced gastrointestinal stromal tumor (GIST) following failure of standard therapy (Rx) [abstract no. 10050]. 2011 ASCO Annual Meeting. J Clin Oncol. 2011;29(Suppl. 15s).Google Scholar
- 54.Van Cutsem E, Sobrero A, Siena S, et al. Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC) [abstract no. 3502]. 2012 ASCO Annual Meeting. J Clin Oncol. 30;(Suppl).Google Scholar
- 55.Regorafenib in subjects with metastatic colorectal cancer (CRC) who have progressed after standard therapy (CONSIGN). ClinicalTrials.gov Identifier: NCT01538680. National Institutes of Health. http://www.clinicaltrials.gov.
- 56.Demetri GD, Reichardt P, Kang Y, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:295–302.PubMedCrossRefGoogle Scholar
- 57.Determination of safety, efficacy, and pharmacokinetics of “regorafenib” combined with pemetrexed and cisplatin in patients with nonsquamous non-small cell lung cancer. ClinicalTrials.gov Identifier: NCT01187615. National Institutes of Health. http://www.clinicaltrials.gov.
- 58.First line treatment of metastatic colorectal cancer with mFOLFOX6 in combination with regorafenib. CORDIAL. ClinicalTrials.gov Identifier: NCT01289821. National Institutes of Health. http://www.clinicaltrials.gov.
- 59.Regorafenib + FOLFIRI versus placebo + FOLFIRI as 2nd line Tx in K-RAS/BRAF mutant metastatic colorectal cancer. ClinicalTrials.gov Identifier: NCT01298570. National Institutes of Health. http://www.clinicaltrials.gov.
- 60.Study to determine safety, pharmacokinetics, pharmacodynamics of BAY73-4506 in combination with mFOLFOX6 or FOLFIRI. ClinicalTrials.gov Identifier: NCT00934882. National Institutes of Health. http://www.clinicaltrials.gov.
- 63.A Study of avastin (bevacizumab) plus crossover fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer. ClinicalTrials.gov identifier: NCT0070010. National Institutes of Health. http://www.clinicaltrials.gov.
- 64.Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30:3499–506.PubMedCrossRefGoogle Scholar